1 3 1
S E P T E M B E R 2 0 1 4 | O U T P AT I E N T S U R G E R Y M A G A Z I N E O N L I N E
Omeros Corporation
Omidria
(phenylephrine and ketorolac injection) 1% / 0.3%
omeros.com
Pricing:
not disclosed
FYI:
Scheduled for a U.S. product launch in the fourth quarter of 2014,
the Omeros Corporation's recently FDA-approved drug Omidria offers
to solve 2 cataract surgery complications at once: intraoperative pupil
constriction and post-operative pain. A mydriatic (pupil-dilating)
agent maintains the opening's size consistently, while the anti-inflam-
matory ketorolac eases recovery and reduces the need to administer
pre-operative NSAIDs. Added to the ocular irrigation solution in use
during surgery, this proprietary compound facilitates predictable pro-
cedures without the need to change surgeons' techniques or routines,
says the company.
O P H T H A L M O L O G Y